ВЛИЯНИЕ ПОВТОРНОЙ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ НА РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ

The results of treatment were analyzed in 308 in patients with non-muscle-invasive (NMI) bladder cancer (BC). The incidence of recurrences was studied in patients with NMI BC who had undergone primary and second look (SL) transurethral resection (TUR). SL TUR is used to identify residual Т1G2−G3 tumors and to specify the stage of the disease, owing to which treatment policy for BC is changed. The authors revealed significant differences between the groups in the rate of early and recurrent NMI BC and its occurrence time during 5 years. The findings show the benefit of relapse-free survival after SL TUR in the T1G2-G3 BC group (p = 0.018). The authors also discuss whether it is reasonable to use SL TUR that allows this procedure to be recommended for patients with G2-G3 NMI BC in routine clinical practice.Проанализированы результаты лечения 308 пациентов с немышечно-инвазивным (НМИ) раком мочевого пузыря (РМП). Изучена частота встречаемости рецидивов у пациентов с НМИ РМП с однократной и повторной (second look – SL) трансуретральной резекцией (ТУР). Посредством SL ТУР выявляются резидуальные опухоли Т1G2−G3, уточняется стадия заболевания, благодаря чему изменяется тактика лечения РМП. Нами выявлены достоверные различия между группами в частоте и сроках возникновения ранних и рецидивов в течение 5 лет. Полученные результаты отражают преимущество безрецидивной выживаемости после выполнения SL ТУР в группах больных РМП T1G2–3 (р = 0,018). Также обсуждается целесообразность применения SL ТУР, позволяющая рекомендовать эту методику пациентам с НМИ РМП G2−3 для рутинной клинической практики

IMPACT OF REPEAT TRANSURETHRAL RESECTION ON TREATMENT RESULTS IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER

<p><em>The results of treatment were analyzed in 308 in patients with non-muscle-invasive (NMI) bladder cancer (BC). The incidence of recurrences was studied in patients with NMI BC who had undergone primary and second look (SL) transurethral resection (TUR). SL TUR is used to identify residual </em><em>Т</em><em>1G2</em>−<em>G3 tumors and to specify the stage of the disease, owing to which treatment policy for BC is changed. The authors revealed significant differences between the groups in the rate of early and recurrent NMI BC and its occurrence time during 5 years. The findings show the benefit of relapse-free survival after SL TUR in the T1G2-G3 BC group (p = 0.018). The authors also discuss whether it is reasonable to use SL TUR that allows this procedure to be recommended for patients with G2-G3 NMI BC in routine clinical practice.</em></p